Vergoeding 2019-2023 voor ATC-subgroep G04BD : Middelen bij urge-incontinentie
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| G04BD02 Flavoxaat (Urispas ®) | 84.011 | 85.273 | 79.812 | 70.870 | 66.122 |
| G04BD04 Oxybutynine (Dridase ®) | 1.528.100 | 1.697.800 | 2.470.800 | 3.595.400 | 4.127.000 |
| G04BD07 Tolterodine (Detrusitol ®) | 682.920 | 705.100 | 646.780 | 673.330 | 832.010 |
| G04BD08 Solifenacine (Vesicare ®) | 11.771.200 | 6.734.900 | 4.280.200 | 4.017.100 | 5.519.800 |
| G04BD10 Darifenacine (Emselex ®) | 1.271.300 | 1.219.200 | 1.171.700 | 1.243.300 | 1.201.100 |
| G04BD11 Fesoterodine (Toviaz ®) | 1.274.500 | 1.247.100 | 1.217.800 | 1.155.700 | 941.310 |
| G04BD12 Mirabegron (Betmiga ®) | 5.701.200 | 6.081.200 | 6.558.300 | 7.363.000 | 8.406.000 |
| Totaal | 22.313.231 | 17.770.573 | 16.425.392 | 18.118.700 | 21.093.342 |